Antithrombotic therapy use in patients with atrial fibrillation before the era of non-Vitamin K antagonist oral anticoagulants: The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase i cohort

Europace

Volumn 18, Issue 9, 2016, Pages 1308-1318

  Huisman, Menno V ^a   Ma, Chang Sheng ^b   Diener, Hans Christoph ^c   Dubner, Sergio J ^d   Halperin, Jonathan L ^e   Rothman, Kenneth J ^f   Teutsch, Christine ^g   Schoof, Nils ^g   Kleine, Eva ^g   Bartels, Dorothee B ^g,h   Lip, Gregory Y H ⁱ  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d Clinica y Maternidad Suizo Argentina   (Argentina)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f RTI HEALTH SOLUTIONS   (United States)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fibrillation; Oral anticoagulation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; DABIGATRAN; NONSTEROID ANTIINFLAMMATORY AGENT; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHINA; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MONOTHERAPY; PAROXYSMAL ATRIAL FIBRILLATION; PERMANENT ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; EUROPE; HEALTH CARE DISPARITY; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; REGISTER; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CHINA; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; HEALTHCARE DISPARITIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MIDDLE EAST; PATIENT SELECTION; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; VITAMIN K;

EID: 84992179944     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euw073     Document Type: Article

References (18)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
2. Lloyd-Jones DM,Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110:1042-6.
3. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006;27:949-53.
4. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: strategies to control, combat, and cure. Lancet 2002;359:593-603.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8.
6. Mandalenakis Z, Von Koch L, Eriksson H, Dellborg M, Caidahl K,Welin L et al. The risk of atrial fibrillation in the general male population: A lifetime follow-up of 50-year-old men. Europace 2015;17:1018-22.
7. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4.
8. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 857-67.
9. Laupacis A, Boysen G, Connolly S, Ezekowitz M, Hart R, James K. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med 1997;157:1237-40.
10. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESCWorking Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;109:769-86.
11. Connolly SJ, EzekowitzMD, Yusuf S, EikelboomJ, Oldgren J, Parekh A et al.Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
12. Graham DJ, Reichman ME,Wernecke M, Zhang R, Southworth MR, Levenson M et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-64.
13. Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 2014;167:329-34.
14. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
15. Chiang CE,Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014;111:789-97.
16. ZhangX, Zhang S, Li Y, Detrano RC,Chen K, LiXet al. Association of obesity and atrial fibrillation amongmiddle-aged and elderly Chinese. Int J Obes (Lond) 2009;33:1318-25.
17. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol 2008;18:209-16.
18. Guo Y,Wang H, Tian Y,Wang Y, Lip GY. Time trends of aspirin and warfarin use on stroke and bleeding events in Chinese patients with new-onset atrial fibrillation. Chest 2015;148:62-72.